#Nuclear Medicine Diagnostic (SPECT and PET) market
Text
Dose Calibrator Market Outlook: Trends and Projections for 2024
The global dose calibrator market is projected to grow steadily at a compound annual growth rate (CAGR) of 3.9% from 2024 to 2032. The market, valued at USD 1.5 billion in 2023, is expected to reach USD 2.1 billion by the end of the forecast period. This growth is driven by the increasing demand for precise radioactive dose measurements in medical applications, particularly in nuclear medicine and radiopharmaceuticals.
Dose calibrators are essential instruments used in nuclear medicine for measuring the radioactivity of isotopes in radiopharmaceuticals. These devices ensure accurate dosing, which is critical in diagnosis and treatment, particularly in cancer therapies and imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). The market’s growth reflects the rising prevalence of chronic diseases, technological advancements, and the increasing global adoption of nuclear medicine.
Get Free Sample PDF: https://www.snsinsider.com/sample-request/4505
Key Market Drivers
Rising Demand for Nuclear Medicine and Radiopharmaceuticals: The growing application of nuclear medicine in the diagnosis and treatment of cancer, cardiovascular diseases, and neurological disorders is a significant driver for the dose calibrator market. Radiopharmaceuticals, which use radioactive isotopes for imaging or treatment, require precise dosage measurements to ensure safety and effectiveness. The increasing use of PET and SPECT imaging techniques, which rely on radiopharmaceuticals, has heightened the demand for dose calibrators globally.
Technological Advancements: The development of more sophisticated and accurate dose calibrators is propelling market growth. Modern dose calibrators feature enhanced precision, user-friendly interfaces, and automation capabilities, reducing the risk of human error in radioactive dose measurement. This makes them indispensable in ensuring that patients receive the correct amount of radiation for their specific medical needs, particularly in oncology where radiation therapy is a key treatment modality.
Growing Awareness of Radiation Safety: Stringent safety regulations in the medical field concerning the handling and administration of radiopharmaceuticals are driving demand for reliable dose calibrators. Accurate dose measurement is essential to minimize exposure to radiation, protecting both patients and healthcare providers. Compliance with regulatory standards set by agencies such as the U.S. Food and Drug Administration (FDA) and the International Atomic Energy Agency (IAEA) is crucial, encouraging the widespread adoption of advanced dose calibrators.
Increasing Prevalence of Cancer and Chronic Diseases: The rise in cancer cases globally is one of the key factors boosting the demand for radiopharmaceuticals and, by extension, dose calibrators. With nuclear medicine becoming a vital tool in cancer diagnosis and treatment, hospitals and diagnostic centers are increasingly investing in accurate dosing technologies. Furthermore, chronic diseases such as cardiovascular disorders, which often require imaging for diagnosis, also contribute to the demand for dose calibrators.
Challenges and Opportunities
Despite its steady growth, the dose calibrator market faces several challenges. High costs associated with the purchase and maintenance of advanced dose calibrators may limit adoption, particularly in developing regions. Additionally, the need for skilled professionals to operate these devices and interpret results adds to operational costs.
However, opportunities abound in emerging markets where healthcare infrastructure is expanding rapidly. Increasing government investments in healthcare, particularly in the Asia-Pacific and Latin America regions, are expected to provide growth opportunities for dose calibrator manufacturers. Moreover, advancements in calibration technology and growing integration with digital health platforms present opportunities for further market expansion.
Regional Insights
North America holds the largest share of the global dose calibrator market, driven by the high adoption of nuclear medicine, robust healthcare infrastructure, and stringent regulatory requirements. The U.S., in particular, is a major market, owing to its advanced healthcare system and the growing prevalence of chronic diseases.
Europe is also a significant market, with increasing investments in nuclear medicine and radiopharmaceuticals. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period due to rising healthcare investments, improving medical infrastructure, and growing awareness of radiation safety protocols.
Future Outlook
As the healthcare industry continues to adopt advanced medical imaging and radiopharmaceutical techniques, the dose calibrator market is expected to maintain steady growth. With a projected CAGR of 3.9% from 2024 to 2032, the market is well-positioned to meet the increasing demand for accurate dose measurements, ensuring safety and precision in nuclear medicine.
In conclusion, the dose calibrator market, valued at USD 1.5 billion in 2023, is set to reach USD 2.1 billion by 2032, driven by advancements in nuclear medicine, rising demand for radiopharmaceuticals, and growing emphasis on radiation safety. This steady growth trajectory will play a critical role in enhancing the accuracy and reliability of medical treatments worldwide.
Other Trending Reports
Immunology Market
Medical Imaging Devices Market
Healthcare Mobility Solutions Market
Diabetes Devices Market
0 notes
Text
Multimodal Imaging Market: Advancing Diagnostic Precision
The Multimodal Imaging market is revolutionizing medical diagnostics by combining multiple imaging techniques to provide comprehensive insights into patient conditions. This integrated approach enhances diagnostic accuracy and treatment planning, driving significant growth in the imaging industry. This article delves into the latest trends, market segmentation, key growth drivers, and leading companies in the multimodal imaging sector.
Market Overview
According to SkyQuest’s Multimodal Imaging Market report, the market is valued at USD 2.26 billion in 2023 and is expected to grow at a CAGR of 4.3% during the forecast period. The rise in chronic diseases, advancements in imaging technology, and increasing demand for precise diagnostics are propelling market expansion.
Request Your Free Sample: - https://www.skyquestt.com/sample-request/multimodal-imaging-market
Market Segmentation
By Modality:
PET/MRI: Combines Positron Emission Tomography (PET) with Magnetic Resonance Imaging (MRI) for detailed anatomical and functional information.
PET/CT: Integrates PET with Computed Tomography (CT) to offer comprehensive imaging for oncology and cardiology.
SPECT/CT: Merges Single Photon Emission Computed Tomography (SPECT) with CT for enhanced diagnostic capabilities in nuclear medicine.
Others: Includes hybrid modalities like PET/MR and PET/CT in various combinations for specific diagnostic needs.
By Application:
Oncology: Utilizes multimodal imaging for accurate tumor detection, staging, and treatment planning.
Cardiology: Enhances the assessment of cardiac conditions and evaluation of heart diseases.
Neurology: Provides detailed brain imaging for diagnosing neurological disorders and monitoring disease progression.
Orthopedics: Assists in the diagnosis and treatment of musculoskeletal conditions.
Others: Includes applications in trauma care, vascular imaging, and preoperative planning.
By End-User:
Hospitals: Major users of multimodal imaging systems for comprehensive diagnostic and treatment services.
Diagnostic Imaging Centers: Specialized facilities offering advanced imaging services to patients.
Research Institutions: Engage in the development and validation of new imaging technologies and applications.
Others: Includes outpatient clinics and specialized medical centers.
Read More at: - https://www.skyquestt.com/report/multimodal-imaging-market
Key Growth Drivers
Technological Advancements: Innovations in imaging technology, such as hybrid imaging systems and software, are driving market growth.
Rising Prevalence of Chronic Diseases: Increased incidence of cancer, cardiovascular diseases, and neurological disorders fuels the demand for advanced diagnostic solutions.
Growing Focus on Precision Medicine: The shift towards personalized healthcare requires detailed imaging for accurate diagnosis and tailored treatment plans.
Increase in Healthcare Spending: Enhanced investment in medical infrastructure and advanced diagnostic tools supports market expansion.
Leading Companies in the Market
SkyQuest’s report highlights key players in the Multimodal Imaging market, including:
Siemens Healthineers
GE Healthcare
Philips Healthcare
Canon Medical Systems
Hitachi Medical Systems
Toshiba Medical Systems Corporation
Hologic, Inc.
Fujifilm Holdings Corporation
Medtronic Plc
Esaote S.p.A.
Take Action Now: Secure Your Report Today - https://www.skyquestt.com/buy-now/multimodal-imaging-market
Challenges and Opportunities
The multimodal imaging market faces challenges such as high costs associated with advanced imaging systems and the need for specialized training for operators. However, opportunities lie in developing cost-effective solutions, expanding applications across various medical fields, and integrating AI to enhance imaging accuracy and efficiency.
Future Outlook
The Multimodal Imaging market is poised for robust growth, driven by continuous technological advancements and an increasing emphasis on precision medicine. Companies that innovate with new imaging modalities and focus on expanding their service offerings will lead the market. For a comprehensive analysis and strategic insights, consult SkyQuest’s Multimodal Imaging Market report.
The Multimodal Imaging market is crucial for advancing diagnostic capabilities and improving patient outcomes. As technology evolves and healthcare needs grow, multimodal imaging will play an increasingly significant role in medical diagnostics. Decision-makers in the healthcare industry should leverage these advancements to stay ahead in this dynamic market. For more detailed information, refer to SkyQuest’s in-depth Multimodal Imaging Market report.
0 notes
Text
The Medical Physics Market is projected to grow from USD 5297.6 million in 2024 to USD 8546.06 million by 2032, expanding at a CAGR of 6.16% from 2024 to 2032.The medical physics market is undergoing significant growth, driven by advancements in healthcare technologies, the increasing prevalence of chronic diseases, and the rising demand for better diagnostic and therapeutic solutions. Medical physics, a field at the intersection of physics and medicine, plays a crucial role in the development and application of these technologies. It encompasses various disciplines such as radiation therapy, diagnostic imaging, nuclear medicine, and radiation protection. As healthcare systems worldwide continue to evolve, the medical physics market is expected to expand substantially, offering new opportunities and challenges.
Browse the full report at https://www.credenceresearch.com/report/medical-physics-market
Market Drivers
1. Technological Advancements: One of the primary drivers of the medical physics market is the rapid advancement in medical technologies. Innovations in imaging techniques, such as MRI, CT, and PET scans, have revolutionized diagnostic procedures, enabling more accurate and early detection of diseases. Similarly, advancements in radiation therapy, including intensity-modulated radiation therapy (IMRT) and proton therapy, have improved the precision and effectiveness of cancer treatments. These technological innovations require the expertise of medical physicists to ensure their safe and effective use, thereby driving demand in the market.
2. Rising Prevalence of Chronic Diseases: The increasing incidence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders is another significant factor contributing to the growth of the medical physics market. As these diseases require sophisticated diagnostic and therapeutic techniques, the role of medical physicists becomes crucial in optimizing treatment protocols and ensuring patient safety. The growing burden of chronic diseases is expected to continue fueling the demand for medical physics services in the coming years.
3. Aging Population: The global aging population is leading to a higher prevalence of age-related diseases, which in turn is boosting the demand for advanced diagnostic and therapeutic solutions. Medical physicists play a vital role in designing and implementing these solutions, particularly in radiation therapy and diagnostic imaging. As the elderly population grows, the need for medical physics expertise is expected to rise, further driving market growth.
Challenges and Opportunities
While the medical physics market presents numerous growth opportunities, it also faces challenges such as the shortage of skilled medical physicists, high costs associated with advanced medical technologies, and regulatory hurdles. However, these challenges also present opportunities for innovation, particularly in training programs, cost-effective technology solutions, and regulatory harmonization.
Key Players:
GE Healthcare
Landauer
Siemens
Krueger-Gilbert Health Physics
Medical Physics Services
West Physics Consulting
Hitachi Aloka Medical Ltd
Fujifilm SonoSite
ClariPi Inc
Versant Medical Physics Services
Alyzen Medical Physics Services
Alliance Medical Physics Services LLC.
Segmentation:
Based on Modality
Diagnostics
Radiographic X-Ray Systems
Fluoroscopic X-Ray Systems
Dental X-Ray Systems
Mammography Systems
Computed Tomography
Magnetic Resonance Imaging
Ultrasound
SPECT
PET
Others
Therapeutics
LINAC
Brachytherapy
Others
Based on Service
Accreditation Assistance
Performance Testing
Physics Testing
Radiation Dose Monitoring
Radiation Safety Training
Treatment Commissioning Services
Safety Surveys
Regulatory & Auditing Services
Others
Based on End User
Hospitals
Ambulatory Surgical Centres
Diagnostic Imaging Centres
Academic & Research Institutes
Based on Region
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East and Africa
Browse the full report at https://www.credenceresearch.com/report/medical-physics-market
About Us:
Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.
Contact:
Credence Research
Please contact us at +91 6232 49 3207
Email: [email protected]
Website: www.credenceresearch.com
0 notes
Text
"Strategic Insights into the Nuclear Imaging Equipment Market: 2024-2033"
Nuclear imaging equipment is at the cutting edge of diagnostic technology, offering unparalleled insights into the function and structure of internal organs through the use of radioactive tracers.
This advanced imaging technique, which includes modalities such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography), allows healthcare professionals to observe metabolic processes and detect abnormalities at a molecular level, providing critical information that traditional imaging methods may miss. Innovations in nuclear imaging equipment have led to enhanced image resolution, reduced scan times, and lower radiation doses, all of which contribute to more accurate diagnoses and better patient outcomes. These advancements enable the early detection of diseases such as cancer, cardiovascular conditions, and neurological disorders, facilitating timely and targeted treatment interventions. The integration of artificial intelligence and machine learning with nuclear imaging is further revolutionizing the field, improving diagnostic precision and operational efficiency. As technology continues to evolve, nuclear imaging equipment is poised to play an increasingly pivotal role in modern medicine, driving progress in disease detection, treatment planning, and personalized care.
#NuclearImaging #PETScan #SPECTScan #DiagnosticImaging #MedicalTechnology #HealthcareInnovation #ImagingAdvancements #RadioactiveTracers #AIInMedicine #PrecisionDiagnosis #MedicalEquipment #CancerDetection #CardiovascularImaging #Neuroimaging #FutureOfHealthcare
0 notes
Text
Evaluating Market Size and Growth Potential in Diagnostic Imaging Market
Market Overview –
The diagnostic imaging market is anticipated to reach USD 49.66 billion by 2032, growing at a CAGR of 4.7% over the forecast period 2023-2032.
The Diagnostic Imaging Market encompasses a wide range of medical imaging technologies used to visualize internal body structures and diagnose various medical conditions. These imaging modalities include X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear medicine techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT).
The diagnostic imaging market is thriving, propelled by advancements in medical imaging technologies. Medical imaging plays a crucial role in disease detection, diagnosis, and treatment planning. With continuous innovation, such as AI integration and portable imaging devices, the market is witnessing sustained growth, meeting the increasing demand for accurate and efficient diagnostic solutions.
In recent years, the diagnostic imaging market has experienced significant growth globally due to several factors. Firstly, there has been increasing demand for diagnostic imaging procedures driven by factors such as aging populations, rising prevalence of chronic diseases, and advancements in imaging technology. Key players in this market include medical device manufacturers, imaging equipment suppliers, healthcare providers, and research institutions, collaborating to develop and commercialize innovative imaging solutions.
Moreover, advancements in imaging technology have led to the development of new imaging modalities with improved resolution, speed, and diagnostic accuracy. These advancements enable earlier detection of diseases, more precise treatment planning, and better monitoring of treatment response, ultimately leading to improved patient outcomes.
Additionally, there is growing interest in personalized imaging approaches tailored to individual patient characteristics, such as genetic profiles, disease stage, and treatment history. Personalized imaging techniques enable healthcare providers to optimize imaging protocols and treatment strategies based on each patient's unique needs, enhancing the efficacy and safety of medical imaging procedures.
Overall, the diagnostic imaging market presents opportunities for growth and innovation as it continues to evolve with advancements in technology and increasing demand for diagnostic imaging services worldwide. Efforts to develop new imaging modalities, improve imaging quality, and expand access to imaging services are essential for advancing healthcare practices and improving patient care.
Market Segmentation –
The global diagnostic imaging market has been segmented on the basis of product, source, and application.
Based on product type, the market has been divided into x-ray equipment, ultrasound imaging systems, nuclear imaging systems, magnetic resonance imaging (MRI), computed tomography (CT) scanners, and other products
The market, by application, has been segmented into gynecology, oncology, orthopedics, cardiology, gastroenterology, neurology, and other applications
The end-user segment has been further divided into hospitals and clinics, diagnostic centers, research institutes, and others.
Regional Analysis –
Regional analysis of the diagnostic imaging market is essential for understanding the adoption, trends, and dynamics of imaging modalities across different geographic regions. Diagnostic imaging plays a crucial role in healthcare by enabling the visualization of internal body structures for diagnosis, monitoring, and treatment planning. Factors such as healthcare infrastructure, reimbursement policies, and prevalence of diseases influence the demand for various imaging technologies in each region.
Developed regions like North America and Europe often lead in the adoption of advanced imaging modalities such as MRI, CT scans, and PET scans due to well-established healthcare systems, high healthcare spending, and early adoption of innovative medical technologies. In contrast, emerging economies in Asia-Pacific and Latin America are witnessing increasing demand for diagnostic imaging, driven by factors such as rising healthcare expenditure, improving access to healthcare services, and growing prevalence of chronic diseases. Additionally, variations in regulatory frameworks and cultural attitudes towards healthcare impact market dynamics and adoption rates across regions.
Conducting a comprehensive regional analysis enables stakeholders to identify market opportunities, tailor their marketing strategies, and address region-specific challenges such as regulatory compliance and market access. By understanding regional nuances, companies can optimize their market penetration efforts and better serve the diagnostic imaging needs of healthcare providers and patients worldwide.
Key Players –
The Diagnostic imaging company profiles include Koninklijke Philips N.V., CANON MEDICAL SYSTEMS CORPORATION, Carestream Health, Esoate SpA, GE Healthcare, Toshiba Medical Systems Corporation, FUJIFILM Holdings Corporation, Siemens Healthcare Private Limited, Hitachi Medical Systems, Hologic Inc., and Shimadzu Corporation.
Related Reports –
Macrolide Antibiotics
Spinal Traction
Performance Enhancing Drugs
Vasectomy
For more information visit at MarketResearchFuture
#Diagnostic Imaging Market#Diagnostic Imaging Market Size#Diagnostic Imaging Market Share#Diagnostic Imaging Market Growth#Diagnostic Imaging Market Trends
0 notes
Text
Radioactive Tracer Market is Estimated to Witness High Growth Owing to Growing Applications in Medical Diagnostics
Radioactive tracers are radioactive compounds used in medical diagnostics for imaging tissues, organs, bones or blood flow and to detect any defects or health issues. These tracers are tagged with radioactive isotopes and injected or inhaled into the body to enable visualization using imaging modalities like PET and SPECT scans.
Market Dynamics:
The global radioactive tracer market is witnessing high growth owing to increasing applications of nuclear medicine techniques in disease diagnosis and growing geriatric population susceptible to neurodegenerative and cardiovascular diseases. Radioactive tracers find wide usage in positron emission tomography (PET) scans to detect cancer, cardiovascular diseases, and brain disorders by tracking the radioactivity in the body. Furthermore, advancements in imaging technologies and introduction of novel radioactive tracers with improved sensitivity and specificity are also fueling market growth over the forecast period.
Radioactive Tracer Market Drivers:
Increasing Application in Medical Imaging
The rising prevalence of chronic diseases such as cancer, cardiovascular diseases and neurological disorders has fuelled the demand for effective diagnosis. Radioactive tracers play a key role in molecular imaging techniques such as positron emission tomography and single photon emission computed tomography scans which are widely used for diagnosis purposes. Their ability to track biological processes in real time makes them invaluable medical tools. With more people gaining access to healthcare globally and greater emphasis being placed on early detection, the medical imaging sector is set to expand significantly which will drive growth opportunities for radioactive tracers.
Growth in PET Radiopharmaceuticals
within the medical imaging domain, Positron Emission Tomography (PET) is one of the most promising techniques owing to the detailed functional information it provides. PET radiotracers labelled with short-lived radioactive isotopes such as fluorine-18, carbon-11, nitrogen-13 and oxygen-15 are increasingly used for oncological, neurological and cardiac applications. The miniaturization of PET technology along with its combination with other modalities such as CT and MRI has augmented its diagnostic power. All of these factors coupled with favourable reimbursement policies have boosted the demand for PET radiotracers and contributed to the increased production of PET isotopes and tracers.
Radioactive Tracer Market Restrain:
Stringent Regulations
Radioactive tracers are closely regulated by various government agencies due to the risks involved in working with radioactive materials. Manufacturers have to comply with strict guidelines at every stage - right from production and quality testing to transportation and clinical use. Significant investments are required to set up and maintain facilities capable of handling radioisotopes safely and as per regulatory standards. Additionally, the expensive licensing and product approval procedures present obstacles especially for new market entrants. While regulations are necessary to ensure radiation safety, the complexity of the regulatory framework has slowed the pace of innovation and commercialization to some extent in this market.
Radioactive Tracer Market Opportunity:
Theragnostic Applications The convergence of therapeutics and diagnostics, referred to as 'theragnostics', holds tremendous potential for personalized medicine. Radioactive tracers play an important role in theragnostic approaches by enabling imaging-guided drug delivery and monitoring treatment responses in real-time. For instance, radiolabelled nanoparticles, antibodies and peptides can help deliver higher concentrations of therapeutic payloads like chemotherapy drugs directly to tumours while also allowing physicians to visualize drug accumulation and distribution with PET/SPECT. This allows safer, more effective outcomes for conditions such as cancer. Continued advancements in theragnostic radiopharmaceuticals development will open up new opportunities for players in the radioactive tracer market.
Radioactive Tracer Market Trend:
Increasing Demand for Custom Tracers One of the emerging trends in the radioactive tracer industry is the rising demand for custom radiotracers tailored to specific clinical or research applications. While pre-designed generic radiotracers work well for common indications, customized tracers allow gathering more detailed disease information. Factors such as mutations in molecular targets, rare conditions and personalized medicine approaches require radiopharmaceuticals synthesised from unusual radioisotopes or radiolabelled novel molecular probes. Companies are exploring contract manufacturing models and tracer libraries to facilitate rapid production of user-defined radiotracers. This has prompted wider isotope production along with investments in flexible synthesis platforms and skilled workforce. The custom radiotracer segment will likely be an area of active growth and differentiation in the coming years.
0 notes
Text
Global Nuclear Medicine Market Size, Trends, Analysis, Growth, Share, Industry Forecast, 2023-2030
Global Nuclear Medicine Market
The Global Nuclear Medicine Market was valued at US$ 5.97 Bn in 2022 estimated to reach US$ 11.59 Bn by 2030, with a CAGR of 8.33% from 2023-2030.
In the field of medicine known as nuclear medicine, numerous ailments such as cancer, cardiac disease, and neurological problems are diagnosed and treated using radioactive materials called radiopharmaceuticals. High-tech cameras allow medical personnel to monitor the radioactive tracers' progress. Additionally, two essential imaging modalities in nuclear medicine are single-photon emission computed tomography (SPECT) and positron emission tomography (PET).
Read More: https://qualiketresearch.com/reports-details/Global-Nuclear-Medicine-Market
Market Drivers
The availability of a strong product pipeline and supportive government programs to increase accessibility to nuclear medicine is anticipated to drive market growth in the coming years. Clinical trials are being conducted on several products, such as betalains, omburtamab, yttrium-90 microspheres, PNT2003, and 177Lu-PNT2002. The U.S. has a favorable reimbursement environment for radiopharmaceuticals is expected to stimulate market expansion.
In addition, therapy requirements for patients are growing improvements in disease diagnosis and therapy as well as the approval of novel nuclear medicine-based technologies. For instance, GE Healthcare announced in September 2021 the introduction of a unique scanner with a new automated workflow feature that delivers an excellent view of cardiac anatomy and pathology to aid physicians in selecting the best course of treatment for a patient.
Market Segmentation
The scope of the Global Nuclear Medicine Market covers segmentation based on Diagnostics, Therapeutics, Applications, and Region.
Based on Diagnostics, the market is segmented into Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET).
Based on Therapeutics, the market is classified into Alpha Emitters, Beta Emitters, and Brachytherapy.
Based on Applications, the market is bifurcated into Cardiology, Neurology, Oncology, and Other Applications.
Request A Sample: https://qualiketresearch.com/request-sample/Global-Nuclear-Medicine-Market/request-sample
Regional Analysis
The Global Nuclear Medicine Market is segmented into 5 main regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The primary market for nuclear medicine is North America.
The United States' booming healthcare industry, rising cancer rates, rising geriatric population, rise in product launches driving up radioisotope usage, and increased initiatives and investments in cutting-edge healthcare solutions for cancer treatment are all expected to contribute to the market's expansion. In the United States, funding for cancer illness research and treatment is likewise rising. The National Centre for Health Statistics (NCHS) of the Centres for Disease Control & Prevention (CDC) has produced data that estimates cancer-related investments might reach up to USD 7,176 million in 2021.
Key Developments
The Department of Nuclear Medicine at PSG Hospitals in Coimbatore, which is outfitted with cutting-edge technology for diagnosing cancer and other disorders, was opened in April 2022 by Health Minister Ma. Subramanian.
A program enabling nuclear medicine facilities the chance to become designated and certified Centres of Excellence in Radiopharmaceutical Therapy was introduced by SNMMI in February 2022. Strict regulatory, training, certification, experience, and performance standards will be met by the centers, resulting in optimal patient selection and radiopharmaceutical therapy outcomes.
Key Players
Mallinckrodt plc., General Electric Co., Medtronic, plc. (Covidien, acquired by Medtronic), Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., IBA Group, Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Advanced Accelerator Applications S.A.
Key Questions Addressed by the Report
• What are the Key Opportunities in Global Bonsai Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
About Us:
QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers.
QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence.
QualiKet Research strive hard to simplify strategic decisions enabling you to make right choice. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition. Our experts provide deep insights which is not available publicly that enables you to take bold steps.
Contact Us:
6060 N Central Expy #500 TX 75204, U.S.A
+1 214 660 5449
1201, City Avenue, Shankar Kalat Nagar,
Wakad, Pune 411057, Maharashtra, India
+91 9284752585
Sharjah Media City , Al Messaned, Sharjah, UAE.
+91 9284752585
0 notes
Text
Middle East and Africa Nuclear Imaging Marketsize at USD 285.3 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the Middle East and Africa Nuclear Imaging Marketsize to grow at a steady CAGR of 2.68% reaching a value of USD 334.37 million by 2029. Major growth drivers for the Middle East and Africa Nuclear Imaging Market include an increasing prevalence of cancer and cardiac ailments. Nuclear medicine has proven highly effective in treating these diseases, with a notable impact on diagnosis, treatment planning, and treatment response assessment in cancer patients. Factors contributing to the rising cancer burden include an aging population, poor dietary habits, smoking, and physical inactivity. According to GLOBOCAN 2020, both Israel and Saudi Arabia reported a substantial number of new cancer cases. It, in turn, is expected to boost the demand for nuclear medicine imaging, particularly in the Middle East and African region. The magnetic resonance imaging market in this area is forecasted to witness healthy growth. Nuclear medicine's crucial role in diagnosing and managing various diseases is identified as a key growth factor for the market. Also, the Middle East and Africa Nuclear Imaging Market growth is fueled by the adoption of key strategies, such as collaborations and partnerships, by industry players. Hence, such aspects are expected to drive the growth of the Middle East and Africa Nuclear Imaging Market during the forecast period. However, high cost of nuclear imaging equipment and services and lack of skilled nuclear medicine are anticipated to restrain the overall market growth during the period in analysis.
Opportunity - Growing Demand for Hybrid Imaging Systems
Hybrid imaging systems, including PET-CT and SPECT-CT, are experiencing growing acceptance in the Middle East and Africa (MEA) region. The utilization of these systems is on the rise as they integrate functional data from nuclear imaging with anatomical details obtained from CT scans. This integration enhances diagnostic capabilities by providing a more comprehensive and detailed understanding of medical conditions. The increasing adoption of hybrid imaging reflects a trend toward advanced and integrated medical technologies, contributing to improved diagnostic accuracy and patient care in the Middle East and Africa healthcare landscape.
Sample Request @ https://www.blueweaveconsulting.com/report/middle-east-and-africa-nuclear-imaging-market/report-sample
0 notes
Text
Nuclear Medicine Market Segment Analysis By Product, Application, End-Use, Region And Forecast Till 2030: Grand View Research Inc.
San Francisco, 17 Nov 2023: The Report Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy)), By Application, By End-use, By Region, And Segment Forecasts, 2023 – 2030
The global nuclear medicine market size is expected to reach USD 22.3 billion by 2030, registering a CAGR of 11.8% over the…
View On WordPress
#Nuclear Medicine Industry#Nuclear Medicine Market#Nuclear Medicine Market 2023#Nuclear Medicine Market 2030#Nuclear Medicine Market Revenue#Nuclear Medicine Market Share#Nuclear Medicine Market Size
0 notes
Text
Medical Imaging Equipment Market Size Expected To Acquire USD 48,786.03 million By 2030 At CAGR of 5.60%
The latest market report published by Credence Research, Inc. “Global Medical Imaging Equipment Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2030. The market for medical imaging equipment has been expanding steadily in recent years, and between 2023 and 2030, it is anticipated to rise at a CAGR of 5.60%. The market was estimated to be worth USD 31,548.9 million in 2022, and it is anticipated to be worth USD 48,786.03 million in 2030.
Medical Imaging Equipment Market Overview:
The Medical Imaging Equipment Market refers to the global industry that produces and sells various devices used to create visual representations of the interior of a body for clinical analysis and medical intervention. These devices play a crucial role in diagnosing, monitoring, and treating various medical conditions by providing valuable insights into the structure and functioning of internal organs and tissues. The market includes a wide range of imaging modalities, each with its own technology and applications.
Types of Medical Imaging Equipment:
Computed Tomography (CT) Scanners: CT scanners use a series of X-ray images taken from different angles to create detailed cross-sectional images of the body. They are especially useful for visualizing internal structures in 3D.
Magnetic Resonance Imaging (MRI) Systems: MRI uses strong magnetic fields and radio waves to generate detailed images of soft tissues, organs, and the nervous system. It's particularly valuable for diagnosing neurological and musculoskeletal conditions.
Ultrasound Machines: Ultrasound imaging uses high-frequency sound waves to create images of internal structures. It's commonly used for monitoring pregnancies, examining organs, and guiding procedures.
Nuclear Medicine Equipment: This category includes equipment like Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scanners. These technologies use radioactive tracers to visualize organ function and metabolism.
Partnerships and Collaborations:
Siemens Healthineers and Novartis: Siemens Healthineers entered into a partnership with Novartis to develop and commercialize assays measuring blood levels of certain therapeutic drugs using Siemens' Atellica Solution immunoassay analyzer. This collaboration aimed to enhance personalized treatment and monitoring of patients.
Philips and B. Braun Melsungen: Philips and B. Braun Melsungen collaborated in 2020 to provide an integrated regional solution for continuous ultrasound-guided regional anesthesia. The collaboration aimed to improve patient care during surgery by combining B. Braun's regional anesthesia expertise with Philips' ultrasound technology.
GE Healthcare and Roche: GE Healthcare and Roche collaborated in 2020 to develop and market digital diagnostics solutions, combining Roche's expertise in in-vitro diagnostics with GE Healthcare's expertise in medical imaging and monitoring.
Acquisitions:
Philips Acquires BioTelemetry: Philips acquired BioTelemetry, a company specializing in remote cardiac diagnostics and monitoring. This acquisition aimed to expand Philips' remote patient monitoring offerings and enhance its digital healthcare solutions.
Siemens Healthineers Acquires Varian Medical Systems: Siemens Healthineers completed the acquisition of Varian Medical Systems, a company known for its advanced radiation therapy solutions for cancer treatment. This acquisition aimed to strengthen Siemens Healthineers' oncology portfolio.
Canon Medical Systems Acquires Delft Imaging Systems: Canon Medical Systems acquired Delft Imaging Systems, a company focused on providing medical imaging solutions for low-resource settings. This acquisition aimed to enhance Canon's efforts to provide healthcare solutions to underserved regions.
Browse 240 pages report By End-User (Hospitals, Diagnostic Imaging Centers, Specialty Clinics, Ambulatory Care Centers) By Technology (Digital Imaging, Analog Imaging, 3D and 4D Imaging, Portable and Point-of-Care Imaging) By Specialty and Advanced Features Contrast-Enhanced Imaging, Functional Imaging, Interventional Imaging, Molecular Imaging) Growth, Future Prospects & Competitive Analysis, 2016 – 2030 - https://www.credenceresearch.com/report/medical-imaging-equipment-market
Here are some of the significant growth factors:
Technological Advancements: Continuous advancements in medical imaging technology, such as MRI, CT scans, ultrasound, and X-ray systems, have played a pivotal role in market growth. Improved imaging quality, faster scans, and reduced radiation exposure have expanded the applications and adoption of these technologies.
Aging Population: The global population is aging, leading to an increased demand for medical imaging services. As people age, they are more likely to require medical imaging for diagnostic purposes and disease management.
Rising Chronic Diseases: The prevalence of chronic diseases such as cancer, cardiovascular diseases, and orthopedic conditions is on the rise. These conditions often require diagnostic imaging for accurate diagnosis and treatment planning.
Emerging Markets: Developing countries are expanding their healthcare infrastructure, increasing access to medical imaging services. This has led to a significant market growth in regions like Asia-Pacific, Latin America, and the Middle East.
Why to Buy This Report-
The report provides a qualitative as well as quantitative analysis of the global Medical Imaging Equipment Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.
Major nations in each region with their import/export statistics
The global Medical Imaging Equipment Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.
Browse Full Report: https://www.credenceresearch.com/report/medical-imaging-equipment-market
Visit: https://www.credenceresearch.com/
Related Report: https://www.credenceresearch.com/report/ambulatory-surgery-centers-market
https://www.credenceresearch.com/report/veterinary-surgical-sutures-market
Browse Our Blog: https://www.linkedin.com/pulse/medical-imaging-equipment-market-grow-steadily-over-cagr-shukla
About Us -
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.
Contact Us:
Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India
0 notes
Text
The Future of the Radiopharmaceutical Injectors Market: Key Insights and Trends
The global radiopharmaceutical injectors market is set to experience significant growth over the next decade, with a projected compound annual growth rate (CAGR) of 7.2% from 2024 to 2032. Valued at USD 27.8 billion in 2023, the market is expected to reach USD 52.3 billion by 2032. This growth is driven by increased demand for advanced imaging techniques, rising prevalence of chronic diseases, and innovations in nuclear medicine.
Radiopharmaceutical injectors are specialized devices used to administer radiopharmaceuticals, which are radioactive compounds used in nuclear medicine for diagnostic imaging and therapeutic purposes. These injectors ensure precise delivery of radiopharmaceuticals into the body, helping healthcare professionals detect and treat various conditions, including cancer, cardiovascular diseases, and neurological disorders.
Get Free Sample PDF: https://www.snsinsider.com/sample-request/4510
Key Market Drivers
Growing Demand for Diagnostic Imaging: The increasing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, is driving the demand for advanced diagnostic imaging. Radiopharmaceuticals are crucial in procedures such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), which provide detailed insights into organ function and disease progression. The need for more accurate and earlier diagnoses is boosting the demand for radiopharmaceutical injectors in hospitals, clinics, and diagnostic centers.
Technological Advancements in Nuclear Medicine: Innovations in nuclear medicine and radiopharmaceutical production are playing a pivotal role in the market’s growth. The development of novel radiopharmaceuticals with enhanced imaging capabilities and targeted therapies is revolutionizing the field of nuclear medicine. Radiopharmaceutical injectors, designed for the precise administration of these compounds, are becoming more advanced, offering greater accuracy, safety, and ease of use. This technological progress is expected to continue driving market expansion.
Rising Incidence of Cancer: The growing global burden of cancer is one of the primary factors propelling the radiopharmaceutical injectors market. Radiopharmaceuticals are extensively used in oncology for both diagnostic imaging and targeted radiotherapy. With the rising incidence of cancer worldwide, there is a heightened need for effective diagnostic tools and treatments. Radiopharmaceutical injectors enable the accurate and controlled delivery of radiotracers and therapeutic agents, contributing to better patient outcomes.
Increasing Use of Targeted Therapies: The shift toward personalized medicine and targeted therapies is also influencing the growth of the radiopharmaceutical injectors market. Radiopharmaceuticals allow for precise targeting of cancer cells, minimizing damage to surrounding healthy tissues. As more targeted therapies are developed, the demand for radiopharmaceutical injectors, which play a critical role in the administration process, is expected to rise.
Challenges and Opportunities
While the radiopharmaceutical injectors market is poised for growth, certain challenges must be addressed. The high cost of radiopharmaceuticals and injectors, coupled with the need for highly skilled personnel to administer these treatments, may limit market penetration in some regions. Additionally, the regulatory environment surrounding radiopharmaceuticals and their administration can be complex, posing barriers for new market entrants.
However, these challenges present opportunities for innovation. Companies are investing in the development of cost-effective radiopharmaceutical injectors and automated systems to improve ease of use and reduce human error. Furthermore, advancements in artificial intelligence (AI) and automation in healthcare are expected to enhance the precision and efficiency of radiopharmaceutical delivery, creating new growth avenues in the market.
Regional Insights
North America currently holds the largest share of the radiopharmaceutical injectors market, driven by the presence of leading healthcare infrastructure, advanced diagnostic technologies, and a high prevalence of chronic diseases. The United States, in particular, is a major player, with significant investments in nuclear medicine research and development.
Europe follows closely, with growing adoption of nuclear medicine techniques and increasing investments in healthcare technologies. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, fueled by rising healthcare expenditures, an increasing focus on cancer diagnostics, and expanding healthcare infrastructure in countries like China, Japan, and India.
Future Outlook
The future of the radiopharmaceutical injectors market looks promising, with continuous advancements in nuclear medicine and radiopharmaceuticals paving the way for new diagnostic and therapeutic applications. As healthcare providers seek more accurate, efficient, and less invasive diagnostic tools, the demand for radiopharmaceutical injectors will continue to grow.
In conclusion, the global radiopharmaceutical injectors market is on a robust growth trajectory, with an estimated CAGR of 7.2% from 2024 to 2032. From a market valuation of USD 27.8 billion in 2023, the market is expected to reach USD 52.3 billion by 2032, driven by technological innovations, increasing demand for advanced diagnostics, and the rising prevalence of chronic diseases. The industry is poised for further breakthroughs that will enhance patient care and revolutionize the field of nuclear medicine.
Other Trending Reports
Defibrillator Market
Healthcare Waste Management Market
PET Scanners Market
Antidepressants Market
0 notes
Text
The global demand for medical imaging reagents was valued at USD 16251.2 Million in 2023 and is expected to reach USD 25646.4 Million in 2032, growing at a CAGR of 5.2% between 2024 and 2032.Medical imaging reagents are essential in modern healthcare, significantly enhancing the diagnostic accuracy and treatment efficacy of various diseases. These reagents, including contrast media, radiopharmaceuticals, and fluorescent dyes, are used to visualize structures and functions within the body, aiding in the early detection, diagnosis, and monitoring of diseases. The global medical imaging reagents market has seen substantial growth, driven by technological advancements, an aging population, and increasing prevalence of chronic diseases.
Browse the full report at https://www.credenceresearch.com/report/medical-imaging-reagents-market
Market Overview
The medical imaging reagents market encompasses a variety of products that improve the visibility of internal organs, tissues, and systems in imaging procedures. These reagents are used in various imaging modalities, including:
1. X-ray and Computed Tomography (CT)
2. Magnetic Resonance Imaging (MRI)
3. Nuclear Medicine Imaging (PET and SPECT)
4. Ultrasound
5. Optical Imaging
Each modality requires specific types of reagents to enhance image clarity and detail. The primary categories of imaging reagents are:
- Contrast Media: Used to enhance the contrast of structures or fluids within the body, making them more visible on imaging.
- Radiopharmaceuticals: Radioactive compounds used in nuclear medicine to diagnose and treat diseases.
- Fluorescent Dyes: Used in optical imaging to highlight specific areas of interest.
Key Drivers
1. Technological Advancements: Continuous innovations in imaging technologies and the development of new and improved reagents have significantly contributed to market growth. For example, advancements in MRI contrast agents have led to better image quality and reduced side effects.
2. Aging Population: The global increase in the elderly population has led to a higher incidence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders. This demographic shift has increased the demand for diagnostic imaging procedures.
3. Prevalence of Chronic Diseases: The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular diseases, has driven the need for advanced diagnostic tools. Early diagnosis through imaging is crucial for effective treatment and management of these conditions.
4. Growing Awareness and Screening Programs: Increased awareness about the benefits of early diagnosis and the implementation of screening programs for various diseases have boosted the demand for imaging procedures, thereby driving the market for imaging reagents.
Market Segmentation
The medical imaging reagents market can be segmented based on product type, application, and geography.
1. Product Type:
- Contrast Media
- Radiopharmaceuticals
- Fluorescent Dyes
2. Application:
- Oncology
- Cardiology
- Neurology
- Gastroenterology
- Others
3. Geography:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Regional Insights
North America: Dominates the medical imaging reagents market, driven by advanced healthcare infrastructure, high healthcare expenditure, and a strong focus on research and development.
Europe: Follows closely, with significant investments in healthcare and increasing adoption of advanced imaging technologies.
Asia-Pacific: Expected to witness the fastest growth due to the rising healthcare expenditure, growing awareness about early diagnosis, and an increasing number of diagnostic imaging procedures.
Latin America and Middle East & Africa: These regions are also expected to see growth due to improving healthcare infrastructure and increasing adoption of advanced medical technologies.
Challenges and Opportunities
Challenges:
- High Cost: The high cost of imaging procedures and reagents can be a barrier, especially in developing regions.
- Side Effects: Some imaging reagents, particularly contrast media, can cause adverse reactions in patients, which can limit their use.
Opportunities:
- Personalized Medicine: The growing trend of personalized medicine offers significant opportunities for the development of targeted imaging reagents.
- Emerging Markets: Developing regions present substantial growth opportunities due to the expanding healthcare sector and increasing demand for advanced diagnostic tools.
Key Players
Bracco Spa
Lantheus Holdings Inc
General Electric Company
Siemens AG
Bayer AG
CMC Contrast AB
Thermo Fisher Scientific Inc
Merck & Co. Inc
Shimadzu Corporation
Koninklijke Philips N.V.
Others
Segmentation
By Type of Reagents
Contrast Agents
Iodinated Contrast Agents
Gadolinium-Based Contrast Agents
Barium-Based Contrast Agents
Microbubble Contrast Agents (used in ultrasound)
Nuclear Imaging Reagents
Technetium
Fluorine
Gallium
Thallium
Fluorescent Dyes
Bioluminescent Substrates
Others
By Imaging Modality
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Positron Emission Tomography (PET)
Ultrasound
X-ray
Nuclear Medicine
By Application
Cardiology
Oncology
Neurology
Orthopedics
Gastroenterology
Nephrology
Others
By End-User
Hospitals and Clinics
Diagnostic Imaging Centers
Research Institutes
Pharmaceutical and Biotechnology Companies
By Product Formulation
Ready-to-use Reagents
Dry Powder Reagents
Liquid Reagents
By Isotope
Radioactive Isotopes
Non-radioactive Isotopes
By Region
North America
The U.S.
Canada
Mexico
Europe
Germany
France
The U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Browse the full report at https://www.credenceresearch.com/report/medical-imaging-reagents-market
About Us:
Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.
Contact:
Credence Research
Please contact us at +91 6232 49 3207
Email: [email protected]
Website: www.credenceresearch.com
0 notes
Text
Radiopharmaceuticals in Nuclear Medicine Market to Eyewitness Massive Growth by 2028
The Latest Released market study on Global Radiopharmaceuticals in Nuclear Medicine market provides information and useful stats on market structure, size and trends. The report is intended to provide cutting-edge market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Besides, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Radiopharmaceuticals in Nuclear Medicine market.
What’s keeping:
Cardinal Health (United States)
GE Healthcare (United States)
Curium (France)
Lantheus Medical Imaging (United States)
Bayer AG (Germany)
Bracco Imaging (Italy)
Eczacýbaþý-Monrol Nuclear Products (Turkey)
Nordion (Canada)
Advanced Accelerator Applications (France)
NTP Radioisotopes (South Africa)
Keep Growing in the Market? Benchmark yourself with the strategic moves and latest Market Share and Sizing of Global Radiopharmaceuticals in Nuclear Medicine market recently published by AMA
Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.
The Radiopharmaceuticals in Nuclear Medicine Market segments and Market Data Break Down 24360
On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
What’s Trending in Market: High Demand due to increasing Initiatives to reduce the demand and supply gap of Mo-99
Market Challenges: Hospital budget cuts and high equipment costs
Market Opportunities: Use of radiopharmaceuticals in neurological applications
Highlights of Influencing Drivers: Rising incidence as well as prevalence of target conditions
Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments
Presented By
AMA Research & Media LLP
0 notes
Text
Nuclear Medicine/Radiopharmaceuticals Market – Trends Forecast Till 2028
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology), Procedures and Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)
The Nuclear Medicine/Radiopharmaceuticals Market size is projected to reach a CAGR of 10.1% from 2021 to 2028.
Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.
Increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99 are some of the factors that have supported long-term expansion for Nuclear Medicine/Radiopharmaceuticals Market.
Request For Free Sample Report: https://www.delvens.com/get-free-sample/radiopharmaceuticals-market-trends-forecast-till-2028
Regional Analysis
North America is expected to account for the largest share of the nuclear medicine market during the forecast period, The large share of North America can be attributed to the development of novel technologies for radioisotope production, government funding, increasing R&D expenditure and company initiatives in the region.
Key Players
Mallinckrodt plc.
General Electric Co. (healthcare division)
Medtronic, Inc.
Bayer AG
Cardinal Health, Inc.
Lantheus Medical Imaging, Inc.
IBA Group
Make an Inquiry Before the Purchase: https://www.delvens.com/Inquire-before-buying/radiopharmaceuticals-market-trends-forecast-till-2028
Recent Developments
In 2021, Bracco entered into a partnership with CardioNavix which will help improve patient access to cardiac PET imaging.
In 2019. Curium acquired MAP Medical, which will help it to increase its footprint in Europe with direct access to Nordic and Baltic countries.
Reasons to Acquire
Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors
Gain authentic and granular data access for Nuclear Medicine/Radiopharmaceuticals Market so as to understand the trends and the factors involved behind changing market situations
Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns
Purchase This Report At: https://www.delvens.com/checkout/radiopharmaceuticals-market-trends-forecast-till-2028
Report Scope
Nuclear Medicine/Radiopharmaceuticals Market is segmented into type, application, procedural volume assessment and region.
On the basis of Type
Diagnostic Nuclear Medicine
Therapeutic Nuclear Medicine
Brachytherapy Isotopes
On the basis of Application
Diagnostic Applications
On the basis of Procedural Volume Assessment
Diagnostic Procedures
Therapeutic Procedures
On the basis of Region
Asia Pacific
North America
Europe
South America
Middle East & Africa
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
0 notes
Text
Radiopharmaceuticals Market
The “Radiopharmaceuticals Market” size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate CAGR of 6.2% over the forecast period 2023 to 2030. Radiopharmaceuticals are a class of pharmaceutical medicines with a significant radioactivity level. Radiopharmaceuticals are pharmaceuticals formulations that contain radioactive isotopes. These medications can be administered intravenously, orally, or interstitially. In addition, compared to X-rays and other external radiation imaging systems, it is a suitable and secure alternative for patients and aids physicians in diagnosis.
Radiopharmaceuticals and nuclear medicine are increasingly utilized in diagnostic imaging and radiotherapy. This has paved the way for the market expansion of radiopharmaceuticals. Nuclear medicine and radiopharmaceuticals aid in diagnosing organs affected by any pathological condition, particularly malignancy. This modality's applications have expanded from oncology to cardiology, neurology, and infection detection due to the rapid development of nuclear imaging technologies, particularly PET/PET-CT.
To Get a Free Sample Click here
Radiopharmaceuticals Market Dynamics:
Drivers:
The radiopharmaceuticals market is driven by several factors, including:
Increasing prevalence of cancer: With the rising incidence of cancer, the demand for radiopharmaceuticals is increasing as they are used in cancer diagnosis, staging, and treatment.
Growing demand for nuclear medicine: Radiopharmaceuticals are an essential part of nuclear medicine, which is increasingly being used for the diagnosis and treatment of various diseases.
Technological advancements in imaging modalities: The development of new imaging modalities, such as PET/CT and SPECT/CT, is driving the demand for radiopharmaceuticals, as these modalities require the use of radiopharmaceuticals.
Favorable regulatory policies: Governments are implementing favorable policies and regulations to promote the use of radiopharmaceuticals in healthcare, which is driving the growth of the market.
Increasing investment in research and development: Pharmaceutical companies are investing heavily in research and development to develop new radiopharmaceuticals and improve the existing ones, which is driving the growth of the market.
Rising geriatric population: With the increasing geriatric population, the incidence of chronic diseases is on the rise, which is driving the demand for radiopharmaceuticals in diagnosis and treatment.
Growing awareness about the benefits of nuclear medicine: As the awareness about the benefits of nuclear medicine and radiopharmaceuticals is increasing among patients and healthcare professionals, the demand for these products is also increasing.
Restraints:
Side-Effects of Radiopharmaceuticals
Numerous adverse effects of radiopharmaceuticals inhibit market expansion. Among the side effects are chills, severe lethargy, difficulty breathing, flushing or redness of the skin, nausea or vomiting, skin rash, hives, itching, severe headache, and abdominal pain. Therefore, these factors inhibit market expansion.
This radiopharmaceuticals market report provides details of new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographies served, and competitive landscape. For more information on the radiopharmaceuticals market, contact Data Bridge Market Research for an Analyst Brief; our team will assist you in making well-informed decisions for market expansion.
Opportunities:
Increasing Demand for Nuclear Imaging Technologies
The development of nuclear imaging technologies, such as PET or PET-CT, has aided in expanding the applications of this modality from oncology to cardiology, neurology, and infection detection. These technological advances have significantly increased the number of PET and SPECT procedures. In the United States, approximately 2,220,300 PET treatments were performed in 2020, up from 2,200,800 in 2019. Consequently, it is anticipated that this factor will increase radiopharmaceutical market revenue.
Growing R&D Activities Associated with Radiopharmaceuticals
Increased radiopharmaceutical-related R&D activities enhanced market growth. In 2022, for example, the first patient dosed in phase III clinical trials for PET radiopharmaceutical imaging agents developed by GE Healthcare was initiated. The strategic approach will help to enhance patient care by identifying adult Parkinson's disease with greater precision. GE Healthcare will expand its radiation patent portfolio. Thus, this factor stimulates market expansion.
Market Segmentation Analysis:
The global Radiopharmaceuticals Market” is Segmented by Radioisotopes, Application, Source, End-user, and Region.
By Radioisotopes
Tec.99
F18
Iodine 131
Lutetium 177
Yttrium 90
Gallium 68
Gallium 67
Rubidium 82
Iodine 123
Iodine 125
Indium 111
Others
By Application
Oncology
Cardiology
Gastroenterology
Neuroendocrinology
Neurology
Nephrology
Others
By Source
Cyclotrons
Nuclear Reactor
By End User
Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers
Cancer Research Institute
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East, and Africa
Competitive Landscape:
The radiopharmaceuticals market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are
Siemens AG
Positron Corporation
Curium
GE Healthcare
Lantheus Holdings Inc.
Sotera Health LLC
Bayer AG
Eckert & Ziegler
Novartis AG, and BWX Technologies Inc.
The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiopharmaceutical market globally.
Siemens AG
Siemens is a technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In addition, Siemens holds a minority stake in Siemens Energy, a global leader in the transmission and generation of electrical power.
Recent Development
In 2021, NorthStar Medical Radioisotopes, LLC, a global radiopharmaceutical developer, and GE Healthcare confirmed an exclusive partnership to manufacture and distribute iodine-123 (I-123) capsules in the U.S. The product will assist GE Healthcare in enhancing its product portfolio and boosting its market position.
In 2021, Noria Therapeutics Inc. and PSMA Pharmaceuticals Inc. were acquired by Bayer AG Targeted both radiotherapy businesses are developing therapeutic and diagnostic radiopharmaceuticals. The acquisition is anticipated to add to Bayer's current nuclear medicine oncology portfolio.
Regional Analysis:
North America dominates the radiopharmaceuticals market because of the huge base of healthcare facilities and increasing overweight population base. Also, wide presence of a huge patient population suffering from chronic diseases such as coronary disorders, cancer, and strokes and rising number of research activities in this region are also boosting the market growth.
Asia-Pacific is expected to witness significant growth due to the growth in government initiatives to raise awareness and increasing research activities in the region. Also, growing availability of the well-established infrastructure, wide presence of major market players, growth in cases of cardiovascular diseases are boosting the growth rate of the market.
About DataM Intelligence:
DataM Intelligence 4Market Research is a market intelligence platform that gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to clients' needs in crucial business areas. DataM Intelligence has an online platform covering industries such as chemicals and materials, agriculture, health care services, animal feed, and food & beverages, among others. Our forum has Insights on markets that uncover the latest market research data distinct from the competition. With coverage across ten major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the Market by providing a complete view of the Market with statistical forecasts. Our strategy-centric framework and value-added services will let individuals and corporates ease access and custom personalization to research and markets.
Contact Us:
For more information: Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
0 notes
Text
Radiopharmaceuticals in Nuclear Medicine Market is Estimated to Witness High Growth Owing to Demand for PET Imaging in Oncology
Radiopharmaceuticals are radioactive compounds that are used for diagnosis and treatment of various diseases. They emit radiation and help in imaging various body parts in medical procedures such as single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Radiopharmaceuticals find major applications in diagnosis and treatment of cancer, heart diseases, neurological disorders, and other abnormalities.
The global radiopharmaceuticals in nuclear medicine market is estimated to be valued at US$6,700.05 Mn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The increasing incidence of cancer and cardiovascular diseases has significantly driven the demand for PET imaging globally. Positron emission tomography (PET) uses radiopharmaceuticals to produce three-dimensional images of functional processes in the body. It plays a vital role in diagnosing, staging, and restaging of various cancers. According to the International Agency for Research on Cancer (IARC), cancer burden worldwide is projected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. PET imaging provides accurate diagnosis and helps in effective cancer treatment planning. This growing cancer burden presents lucrative opportunities for growth of radiopharmaceuticals used in PET scans. Development of new radiotracers for disease diagnostics using PET imaging technique will further support the demand for radiopharmaceuticals over the forecast period.
Porter's Analysis
Threat of new entrants: Low capital requirement and established distribution channels lower barriers to entry. However, stringent regulatory approvals and need for specialized infrastructure and human resources pose significantentry barriers.
Bargaining power of buyers: Large pool of suppliers and differential product offerings empowers buyers. Switching costs are low.
Bargaining power of suppliers: Specialized product expertise and compliance requirements grant suppliers a differentiated position of strength in negotiations.
Threat of new substitutes: Alternate diagnostic techniques pose substitutive threats but limited success so far due to advantages of nuclear medicine diagnostics.
Competitive rivalry: Intense competition due to low differentiation and prominence of few global leaders. Collaboration and acquisitionare common competitive strategies.
SWOT Analysis
Strengths: Non-invasive diagnostic technique. High diagnostic accuracy. Wide application scope across disease areas.
Weaknesses: High infrastructure and skilled workforce requirements. Limited product differentiation. Supply chain vulnerabilities.
Opportunities: Emerging theranostics applications. Personalized medicine trends. Aging demographics driving disease prevalence.
Threats: Stringent regulations. Reimbursement reimbursement uncertainties. Substitutive diagnostic technologies.
Key Takeaways
The global radiopharmaceuticals in nuclear medicine market is expected to witness high growth over the forecast period. Key regional markets include North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The Asia Pacific region is expected to be the fastest growing market owing to increasing healthcare investments, rising disease incidence, and growing adoption of nuclear medicine diagnostics.
Key players operating in the radiopharmaceuticals in nuclear medicine market include Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company, Bracco S.p.A., Bayer AG, Advanced Accelerator Applications, S.A., Eli Lilly and Company, Nihon Medi-Physics. Co. Ltd., FUJIFILM Toyama Chemical Co., Ltd., Jubilant Life Sciences Ltd., Samyoung Unitech, and DuChemBio, Inc.
0 notes
Last Seen Blogs
